ACR Convergence 2023 Archives - Page 56 of 177

Abstract Number: 1329

R851, a Potent Second Generation IRAK1 and IRAK4 Inhibitor Suppresses IL-6 in Vitro and in Vivo for the Treatment of Rheumatoid Arthritis
Abstract Number: 0081

RA Disease Activity Influence the Frequency and Phenotype of Citrulline Reactive CD4 T Cells in DRB1*04:04 ACPA+ RA Patients
Abstract Number: 0054

RA Monocytes and Monocyte-Derived Macrophages Display Heightened Inflammatory Responses, Reduced Endocytic Capacity and Distinct TET Expression Compared to PsA Monocytes
Abstract Number: 0909

Rab4A Controls the Depletion of IL-2 in CD4+ T Cells via Enhanced CD38 Expression: Potential Involvement in Proinflammatory Lineage Development in Systemic Lupus Erythematosus
Abstract Number: 0999

Race, Payer, and Hospital Factors Are Associated with Post-primary Total Hip Arthroplasty Healthcare Utilization
Abstract Number: 2087

Racial and Ethnic Diversity in Pediatric Fellowships: Fortifying the Pipeline
Abstract Number: 1021

Racial Disparities Between Black and White Patients in Joint Replacement Surgery: A Systematic Review
Abstract Number: 1624

Racial Disparities Impact Achieving LLDAS and Glucocorticoid Use in Pediatric Lupus: A CARRA Registry Study
Abstract Number: 1212

Racial Disparities in Comorbidities and Perception of Physical Health in Systemic Lupus Erythematosus
Abstract Number: 1481

Racial Disparities in Lupus Nephritis: A Nationwide Analysis
Abstract Number: 0190

Racial Disparities in Self-reported Extent and Reasons for Nonadherence in SLE
Abstract Number: 0646

Racial Variability in Immune Responses Only Partially Explains Differential Systemic Sclerosis Disease Severity
Abstract Number: 0490

Racial/Ethnic Differences in Psoriatic Arthritis Patient Responses Regarding Disease Burden, Treatment, and Communication with Care Team
Abstract Number: 0820

Radiographic and Pain Outcomes from a Phase 3 Extension Study Evaluating the Safety and Efficacy of Lorecivivint in Subjects with Severe Osteoarthritis of the Knee (OA-07): 36 Month Single Blind and Placebo Crossover Phase Results
Abstract Number: 0858

Randomized, Controlled, Double-Blind Trial on the Impact of Rosuvastatin on Sublinical Markers of Atherosclerosis in Patients with ANCA-Associated Vasculitis
Abstract Number: 2576

Rapid Onset of Response in Adult Dermatomyositis Patients Receiving Anti-interferon β (PF-06823859): Results of a Phase 2, Double-blind, Randomized, Placebo-Controlled Study
Abstract Number: 1391

Rates of Remission in Patients with Axial Spondyloarthritis Treated in Tertiary Care
Abstract Number: 0957

Rationale for Targeting Insulin-like Growth Factor Signalling in Systemic Sclerosis
Abstract Number: 2091

Reach and Representativeness of Participants in an Evidence-Based, Community-Delivered Physical Activity Intervention in Adults with Arthritis
Abstract Number: 0865

Reactive Oxygen Species-scavenging Nanoparticles Target Macrophage Polarization for Osteoarthritis Therapy
Abstract Number: 0452

Real Life Safety and Survival of Targeted Therapies in Arthritis Patients over Age of 65
Abstract Number: 1319

Real World Data on Antifibrotics in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients
Abstract Number: 0428

Real World Patterns of Advanced Therapy Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort
Abstract Number: 0725

Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Abstract Number: 2589

Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Systemic Lupus Erythematosus
Abstract Number: 0973

Real-World Comparative Effectiveness Study of Janus Kinase Inhibitors Compared to Biologic Disease Modifying Antirheumatic Drugs in Korean Patients with Rheumatoid Arthritis
Abstract Number: 0808

Real-World Disease Monitoring Patterns in Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Veterans Affairs Health Care System
Abstract Number: 2175

Real-World Drug Persistence of GP2015, an Etanercept Biosimilar, in Patients with Rheumatoid Arthritis: Results from the Multi-Country COMPACT Study
Abstract Number: 0424

Real-World Effectiveness of Upadacitinib in Patients with Moderate/Severe Rheumatoid Arthritis: 6-Month Data from the Observational UPHOLD Study
Abstract Number: 2533

Real-world Evidence for Assessing Mortality Disparity Between the Patients with Rheumatoid Arthritis and the General Population in Japan: Results from the IORRA Study
Abstract Number: 0855

Real-world Experience with Avacopan in ANCA Vasculitis: A Multi-center Retrospective Cohort Analysis
Abstract Number: 1181

Real-World Myositis Antibody Frequency and Patient Awareness
Abstract Number: 0681

Real-World Outcomes for Remission Induction in Working-Age Adults with Severe Anti-Neutrophil Cytoplasmic Antibody-associated Vasculitis
Abstract Number: 2164

Real-world Persistence of Initial Targeted Therapy Strategy in Monotherapy versus Combination Therapy in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Abstract Number: 2109

Real-world Positivity of 14-3-3η Protein in Rheumatoid Arthritis
Abstract Number: 2246

Real-World Switching and Discontinuation Patterns for Biologic Disease-Modifying Antirheumatic Drugs in Patients with Active Psoriatic Arthritis in Japan
Abstract Number: 0592

Real-World Treatment Patterns in Patients with Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)
Abstract Number: 1123

Real-world Trends in the Use of Immunomodulation as Co-therapy to Pegloticase: Claims-based Findings Since 2016
Abstract Number: 1619

Receipt of Antimicrobial Prophylaxis in U.S. Medicare Beneficiaries Initiating Immunosuppressive Medications for ANCA Vasculitis
Abstract Number: 1340

Recent Trends in Treatment Patterns for Rheumatoid Arthritis in Response to Emerging Data
Abstract Number: 1018

Recognizing Rural Healthcare Disparities in Pain Assessment for Autoimmune Rheumatologic Diseases
Abstract Number: 0691

Recognizing the New Disorder “Idiopathic Hypocryoglobulinaemia” in Patients with Previously Unidentified Clinical Conditions
Abstract Number: 0751

Recombinant Zoster Vaccination Among U.S. Veterans Receiving Immunosuppressive Medications 2017-2023
Abstract Number: 0879

Recommendations for a Standardized Approach to Histopathologic Evaluation of Synovial Membrane in Murine Models of Experimental Osteoarthritis
Abstract Number: 2395

Recommendations for Early Referral of Patients with Suspected Polymyalgia Rheumatica: An Initiative from the International Giant Cell Arteritis and Polymyalgia Rheumatica Study Group
Abstract Number: 0148

Recreational Activities in Adults with Rheumatoid Arthritis: Relevance, Difficulty, and Associations with Clinical Outcomes
Abstract Number: 2293

Recurrent Intracellular Infections Cluster Together in Patients of SLE with Lymphopenia and Active Disease
Abstract Number: 0959

Redirecting Macrophage Immunophenotype Attenuates Inflammation and Fibrotic Activation in Systemic Sclerosis
Abstract Number: 1705

Reduced DNASE1L3 Activity and Increased Anti-NET Protective Antibodies Contributes to Accumulation of Neutrophil Extracellular Traps in Pediatric SLE Patients
Abstract Number: 0090

Reduced Frequency of RORγt+ Regulatory T Cells Is Associated with Secukinumab Response in Axial Spondyloarthritis
Abstract Number: 1917

Reducing Inadvertent Antifilarial Antibody Testing at an Academic Medical Center: A Quality Improvement Project
Abstract Number: 1082

Reducing No-shows and Late Cancellations at an Academic Medical Center Subspecialty Clinic
Abstract Number: 1842

Reduction in the Concomitant Ordering of Erythrocyte Sedimentation Rate and C-Reactive Protein Within the Rheumatology Clinics at an Academic Medical Center
Abstract Number: 0545

Referral Pattern and Factors Associated with Time to Diagnosis for Lupus in India- multicentric Data from the SLE Special Interest Group (SIG) of the Indian Rheumatology Association (IRA)
Abstract Number: 1128

Refractory Inflammatory Ocular Pathology and Treatment with Janus Kinase Inhibitors. Multicenter Study and Literature Review
Abstract Number: 1309

Refractory RA Patients for Targeted Therapies in Real Life
Abstract Number: 2523

Region, Race, and Hospital Factors Impact Length of Stay and Hospital Charges Post-primary Total Knee Arthroplasty
Abstract Number: 2195

Regional Differences in Clinical Phenotype of Axial Spondyloarthritis. Results from the International Map of Axial Spondyloarthritis (IMAS)
Abstract Number: 0819

Regression to the Mean for Physical Function and Quality of Life in Trials for Symptomatic Knee Osteoarthritis
Abstract Number: 1787

Regulatory Role of JAK-1/TYK2 Signaling on the Pannus Formation: Novel Mechanisms for JAK Inhibitors in Psoriatic Disease
Abstract Number: 2414

Relapse in Giant Cell Arteritis Treated with Tocilizumab. Predictive Factors
Abstract Number: 2301

Relapse in Japanese Patients with Newly Diagnosed SLE and Its Clinical Characteristics in Daily Clinical Practice: A Single Center Experience in Recent 10 Years
Abstract Number: 2382

Relapse of Patients with ANCA-associated Vasculitis Who Are on Dialysis
Abstract Number: 1949

Relapse of Rapidly Progressive Interstitial Lung Disease in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibody-Positive Dermatomyositis
Abstract Number: 1172

Relapse Rate After Glucocorticoid-free Remission in Idiopathic Inflammatory Myopathies with Validation of the International Myositis Assessment & Clinical Studies Group (IMACS) Criteria for Remission and Relapse
Abstract Number: 1152

Relation Between Positive MPO-ANCA Antibodies And: Associated Diseases, Anca-associated Vasculitis Specificty, Severity and Prognosis. Study from a Single University Hospital
Abstract Number: 2524

Relation of Pain Sensitivity to Forces While Walking in Adults with and Without Knee Pain: The Multicenter Osteoarthritis (MOST) Study
Abstract Number: 2104

Relationship Between Frailty and Large Joint Symptoms in Rheumatoid Arthritis Patients
Abstract Number: 0025

Relationship Between Genetic Variants in Cannabinoid Receptor 2 and Self-Reported Effectiveness of Cannabis for Pain Management in Rheumatoid Arthritis
Abstract Number: 0286

Relationship Between High Resolution Computed Tomography(HRCT) Quantitative Scores and Physiological and Clinical Features in Antisynthetase Syndrome Related Interstitial Lung Disease
Abstract Number: 1277

Relationship Between Quality of Life and the Region of the Affected Joints in Japanese Patients with Rheumatoid Arthritis: A Cross-sectional Study
Abstract Number: 1024

Relationship Between Race and Ethnicity, Time to Diagnosis, and Disease Activity for Children with Juvenile Idiopathic Arthritis in the CARRA Registry
Abstract Number: 2223

Relationship Between Sleep Quality, Disease Activity, and Psychological Factors in Patients with Axial Spondyloarthritis: A Cross Sectional Study
Abstract Number: 1195

Relationship of Depth-Specific Subchondral Bone Mineral Density to MRI Cartilage Worsening: The Multicenter Osteoarthritis Study
Abstract Number: 0316

Relationship of Sensitization to Pain Severity in Patients with Knee Osteoarthritis
Abstract Number: 0226

Relationships Among Parameters of Mineral Metabolism and Bone Turnover During Acute COVID-related Hospitalization and Subsequent Follow Up: A Pilot Study
Abstract Number: PP05

Relief Redefined: A Patient’s Journey to Reducing the Impact of Her PsA Flare Ups
Abstract Number: 2551

Remission and Low Disease Activity (LDA) in Patients with SLE Treated with Belimumab (BEL): Results from a Large Integrated Analysis
Abstract Number: 2334

Remission Attainment in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period
Abstract Number: 0302

Remission in Anti-HMGCR Positive Immune-mediated Necrotizing Myopathy Without the Use of Glucocorticoids: A Multicentric Study of 24 Patients
Abstract Number: 0533

Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and b/tsDMARDs in Daily Practice?
Abstract Number: 0683

Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Abstract Number: 1313

Remotely Supervised Weight Loss and Exercise Training Improves Disease Activity and Patient Reported Outcomes in Older Patients with Rheumatoid Arthritis
Abstract Number: 1440

Removal of Methotrexate in Patients with Active Psoriatic Arthritis with Newly Induced Ustekinumab Treatment Leads to a Delayed Response in DAPSA and DAS28 Within the First 16 Weeks
Abstract Number: 0740

Renal Arteriosclerosis in Index Lupus Nephritis Biopsies Predicts Future Cardiovascular Disease
Abstract Number: 1519

Renal Complications Following Autologous Stem Cell Transplantation for Systemic Sclerosis
Abstract Number: 0595

Renal Involvement in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period
Abstract Number: 2493

Renal Prognosis of Dialysis-dependent Patients at Baseline in ANCA-associated Vasculitis
Abstract Number: 2380

Renal Survival Rate of ANCA-associated Vasculitis in Korea: A Nationwide Population-Based Study Using Claims Data
Abstract Number: 0684

Report on Twelve Patients with Diffuse Alveolar Hemorrhage in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Abstract Number: 2459

Reporting of Race and Ethnicity in Lupus Publications in High-impact Rheumatology Journals
Abstract Number: 0673

Reporting of Race, Ethnicity, Sex, Gender, Socioeconomic Status and Representativeness of Race and Ethnicity in ANCA-associated Vasculitis Randomized Trials
Abstract Number: 0194

Reproductive Health Conversations with a Primarily Hispanic Systemic Lupus Erythematosus Population: Influences and Barriers
Abstract Number: 0191

Reproductive Health Discussions Between Rheumatology Providers and Systemic Lupus Erythematosus Patients: A Survey of English and Spanish-Speaking Patients
Abstract Number: 1356

Reproductive History and HPV Vaccination Awareness Among Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 1348

Reproductive Outcomes for Women with Vasculitis
Abstract Number: 2204

Residual Disease Activity in Canadian Patients with Axial Spondyloarthritis: Results from a Multi-registry Analysis (UNISON-Axial SpA)
Abstract Number: 1058

Resolution of Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis While Maintaining Active Treatment with Checkpoint Inhibitors
Abstract Number: 0401

Resolution of Swollen Joint Count Is an Important Clinical Objective in Early Rheumatoid Arthritis : Analysis of the UCLouvain Brussels ERA Cohort and Comparison with the Remission Composite Index
Abstract Number: 1928

Response to Sars-Cov2 Vaccination in Rheumatic and Neurological Patients Treated with Different Immunosuppressive Therapies
Abstract Number: 1955

Responsiveness and Minimal Important Difference of PROMIS Pain Interference, Fatigue, and Physical Function Forms in Adults with Idiopathic Inflammatory Myopathies
Abstract Number: 2159

Results of a 24-week Open-label, Non-interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis After Switching from Anti-B-cell Therapy During the SARS-COV-2 Pandemic
Abstract Number: 2338

Results of Single-Arm, Phase 1b Study of Anti-C1q Treatment (ANX009) Show That the Classical Pathway Is a Key Driver of Complement Activation and Consumption in Patients with Active Lupus Nephritis
Abstract Number: 0186

Retention in Rheumatology Care and on Hydroxychloroquine and SLE Outcomes by Neighborhood Disadvantage: A Medicare Cohort Study of Acute Care and Kidney Failure
Abstract Number: 1475

Retrospective Study of Obesity on Clinical and Immunological Features in Systemic Lupus Erythematosus Using AI Software Deep 6 and EPIC Slicer Dicer
Abstract Number: 2359

Reversal of the Activation State of Pro-fibrotic CD206 Positive Macrophages by Therapeutic Peptide AUR300 in Systemic Sclerosis
Abstract Number: 0173

Review of Published Literature Reporting Economic Burden of Treatment Switching in Rheumatoid Arthritis
Abstract Number: 0446

Review of Rheumatoid Arthritis Treatment Landscape During the COVID-19 Pandemic
Abstract Number: 1151

Revised IWOS Criteria for Ocular Sarcoidosis: A 2019 Review of the 2009 Criteria in a Study of 384 Patients from a Single University Hospital
Abstract Number: 1827

Revolutionizing Fibromyalgia Treatment: Exploring the Efficacy of a New FDA Cleared Photoceutical Device
Abstract Number: 1014

Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Therapy and Subsequent Referrals to Rheumatologists at a Private vs Public Medical Center in Los Angeles: Ramifications for Health Disparities
Abstract Number: 2110

Rheumatoid Arthritis and Changes in Pulmonary Function Measures on Spirometry in a Prospective Longitudinal Cohort of Smokers
Abstract Number: 0989

Rheumatoid Arthritis and Risk of Migraine: A Population-based Nationally Representative Cohort
Abstract Number: 0454

Rheumatoid Arthritis Disease Activity Indices Assess More Than Inflammation: 29%-36% of Patients with Moderate or High DAS28–ESR or CDAI Have 0 or 1 Swollen Joints, but Positive Screens on MDHAQ FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen) Indices
Abstract Number: 0995

Rheumatoid Arthritis Early Diagnostic Clinic: A Web-based Referral Tool Serving Ethnic Minority Patients
Abstract Number: 1299

Rheumatoid Arthritis Patients Who Never Use a Biological During Their Disease Course Represent a Subgroup of Patients Likely to Achieve Sustained DMARD-free Remission
Abstract Number: 1274

Rheumatoid Arthritis Patients, Achieving Low Disease Activity State or Remission, Still Demonstrate Significant Hand Disability, as Assessed by Functional Dexterity Test: A Disconnection Between CDAI and Functional Hand Assessment
Abstract Number: 1333

Rheumatoid Arthritis-associated Lymphoproliferative Disorders: A Multi-center Analysis of Clinical Outcomes and Evaluation of Anti-rheumatic Drugs After LPD Onset
Abstract Number: 1772

Rheumatoid Arthritis-Specific Rheumatoid Factors Develop in Some COVID-19 Patients
Abstract Number: 1802

Rheumatologic Disorder Diagnostic Testing Patterns:Real World Evidence from a National Laboratory Database
Abstract Number: 0340

Rheumatology Patients’ Experiences of a Nationwide Transition to an Adalimumab Biosimilar: A Cross-Sectional Study
Abstract Number: 0765

RheumMadness and TheMednet: The Impact of a Collaboration Between Independent Educational Initiatives
Abstract Number: 2260

Right Insular Cortex-Thalamic Functional Connectivity as a Potential Marker for Fatigue in Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome
Abstract Number: 0129

Rising Incidence and High Mortality of Systemic Sclerosis: A Population-based Cohort Study (2010-2020)
Abstract Number: 0743

Risk and Temporal Trends of Heart Failure Subtypes in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study
Abstract Number: 2530

Risk Evaluation of Osteoporotic Fractures Following Lung Transplantation (LT): A Retrospective Cohort Study Conducted at an International Transplant Center
Abstract Number: 2509

Risk Factors and Mortality of Immune Checkpoint Inhibitor-Induced Flares of Pre-Existing Rheumatoid Arthritis: An Analysis Accounting for Competing Risk of Death and Immortal Time Bias
Abstract Number: 0224

Risk Factors and Outcomes for Repeat COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Case-control Study
Abstract Number: 0987

Risk Factors and Predictors of Disease Activity in Rheumatoid Arthritis and Psoriatic Arthritis: Data from the Mexican Adverse Events Registry (BIOBADAMEX)
Abstract Number: 1298

Risk Factors Associated with Venous Thromboembolism in Rheumatoid Arthritis in Clinical Practice
Abstract Number: 2527

Risk Factors for Bone Loss in Systemic Lupus Erythematosus
Abstract Number: 2052

Risk Factors for Hospitalization for SARS-CoV-2 in Pediatric Patients with Rheumatic Diseases: A Systematic Review and Meta-analysis
Abstract Number: 1479

Risk Factors for Human Papillomavirus Cervical Infection and Clearance in Patients with Systemic Lupus Erythematosus: The PAPILUP Study
Abstract Number: 0680

Risk Factors for Hypogammaglobulinemia and Association with Relapse and Severe Infections in ANCA-Associated Vasculitis: A Retrospective Single-Centre Cohort Study
Abstract Number: 0564

Risk Factors for Immune Thrombocytopenia in Systemic Lupus Erythematosus and Generation of a Predictive Model to Assess Its Risk of Development
Abstract Number: 1291

Risk Factors for Major Adverse Cardiovascular Events and Malignancies in Patients with Rheumatoid Arthritis in a Real-World Setting in Japan
Abstract Number: 0272

Risk Factors for Severe Outcome in Susac Syndrome: A National Cohort Study
Abstract Number: 1455

Risk Factors of Cytomegalovirus Reactivation and Disease in Patients with Systemic Lupus Erythematosus
Abstract Number: 0115

Risk Factors of First Thrombosis in Obstetric Antiphospholipid Syndrome
Abstract Number: 1281

Risk of Cancer in Patients with Rheumatoid Arthritis Under Tocilizumab: Data from the French National Registry REGATE
Abstract Number: 0528

Risk of Cardiovascular Disease Associated with Long-term Use of NSAIDs in Ankylosing Spondylitis
Abstract Number: L11

Risk of Cardiovascular Events According to Biological Agent Exposure in Patients with Ankylosing Spondylitis: A Korean Population-based Study
Abstract Number: 0606

Risk of Damage Progression with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus
Abstract Number: 1485

Risk of Diabetes Mellitus in Systemic Lupus Erythematosus: Systematic Review and Meta-analysis
Abstract Number: 2560

Risk of Gastrointestinal Perforation Among Patients with Giant Cell Arteritis Who Received Tocilizumab
Abstract Number: 0206

Risk of Hepatitis B Virus Reactivation in Patients with Rheumatoid Arthritis Receiving JAK Inhibitor or IL-6 Inhibitor: A Systematic Review and Meta-Analysis
Abstract Number: 0742

Risk of Incident Gout Associated with Initiation of Sodium-glucose cotransporter-2 Inhibitors versus Other Second-line Agents Among Metformin Users with Type 2 Diabetes
Abstract Number: 0247

Risk of Incident Gout Following Exposure to Recombinant Zoster Vaccine in Adults Aged ≥50 Years in the United States
Abstract Number: 0968

Risk of Incident Heart Failure and Heart Failure Subtypes in Patients with Rheumatoid Arthritis
Abstract Number: 1073

Risk of Inflammatory Central Nervous System Diseases Among New Users of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Abstract Number: 2406

Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study
Abstract Number: 0453

Risk of Lung Cancer in Veterans with Rheumatoid Arthritis in Relation to Use of Conventional versus Biologic or Targeted Synthetic DMARDs
Abstract Number: 2385

Risk of Major Adverse Cardiovascular Events in ANCA-associated Vasculitis
Abstract Number: 0672

Risk of New-onset Depression in Patients with Systemic Sclerosis : A Nationwide Population-based Study
Abstract Number: 0204

Risk of Severe Infections Associated with Immunoglobulin Deficiency Under Rituximab Therapy in Immune Mediated Inflammatory Diseases
Abstract Number: 2116

Risk of Tuberculosis in Patients with Rheumatoid Arthritis: A Nationwide Population-based Cohort Study
Abstract Number: 1179

Rituximab in the Treatment of Interstitial Lung Disease Associated with the Antisynthetase Syndrome
Abstract Number: 1512

Rituximab Objective Outcome Measures Trial in SLE (ROOTS): Randomised and Rescue Therapy Outcomes from a Randomised Controlled Trial
Abstract Number: 1956

Rituximab Treatment in Adult Patients with Idiopathic Inflammatory Myositis (IIM): A Systematic Review and Meta-analysis
Abstract Number: 1076

Rituximab-Associated Hypogammaglobulinemia in Patients with Rheumatic Diseases: A Multicenter Retrospective Observational Study
Abstract Number: 0874

RNA-Binding Proteins That Are Highly Expressed and Enriched in Healthy Cartilage but Suppressed in Osteoarthritis
Abstract Number: 0729

ROCK1 Orchestrates B-cell Differentiation Under Stress
Abstract Number: 0862

Role of CRTAC1 as a Biomarker of Osteoarthritis
Abstract Number: 1114

Role of Dual-energy Computed Tomography (DECT) in Detection of Carotid Artery Monosodium Urate Deposition in Patients with Gout
Abstract Number: 1778

Role of GITR/GITRL Interaction in Modulating T Helper 9, T Helper 17 and T Regulatory Response in Psoriatic Arthritis
Abstract Number: 0796

Role of Group 2 Innate Lymphoid Cells in the Pathogenesis of Rheumatoid Arthritis
Abstract Number: 0917

Role of Immunoglobulin Polygenic Risk in Systemic Lupus Erythematosus
Abstract Number: 2353

Role of Insulin-like Growth Factor Binding Protein-7 (IGFBP7) in Pulmonary Hypertension Pathogenesis and as a Biomarker Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Abstract Number: 2405

Role of Mitochondria in Activation of Platelets in Giant Cell Arteritis
Abstract Number: 1771

Role of Periostin in the Pathophysiology and Accurate Diagnosis of Interstitial Lung Disease Associated with Autoimmune Diseases
Abstract Number: 0207

Role of Pneumocystis Jirovecii Pneumonia Prophylaxis with Trimethoprim-Sulfamethoxazole Among Patients with Autoimmune Inflammatory Diseases Receiving High-Dose Glucocorticoids: A Systematic Review and Meta-Analysis
Abstract Number: 2506

Role of TGF-β Activated Kinase 1 in Cytokine-Driven Juvenile Idiopathic Arthritis Synovial Fibroblasts Activation
Abstract Number: 0016

Role of TP53 in Inflammatory Reprogramming of Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 2429

Romosozumab versus Denosumab in High-risk Patients Treated with Glucocorticoids: Interim 12-month Results from a Pilot Randomized Controlled Trial
Abstract Number: 2088

Room for Racial and Ethnic Diversity in Adult Rheumatology Fellowship Pipeline
Abstract Number: 0455

Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Inhibits Peripheral T Cell Proliferation and Cytokine Secretion and Reduces Circulating PD-1 High Expressing CD4 and CD8 T Cells: Results from a Phase 1 Healthy Volunteer Clinical Trial
Abstract Number: 1484

Ruminococcus Implicated in the Clinical Development of Lupus Nephritis: A Systematic Review of the Literature
Abstract Number: 0941

RUNX1 Expression and Binding Site Accessibility Is Associated with Increased Disease Severity in Systemic Sclerosis
Abstract Number: 1759

Runx1 Is a Key Transcription Factor That Drives Synovial Fibroblast Pathogenicity in Rheumatoid Arthritis